Amphista Therapeutics
PrivateLast Round
Series B
Extension
Dec 13, 2022
Total Funding Raised
$60.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Amphista Therapeutics is a biotechnology company that develops next-generation targeted protein degradation therapeutics for the treatment of cancer and other severe diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amphista Therapeutics Comparables
Compare Amphista Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 89% | |
| Pin Therapeutics | 84% | |
| Dunad Therapeutics | 84% | |
Amphista Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 13, 2022 | ||||
| Series B | Mar 17, 2021 | ||||
| Series A | Apr 7, 2020 | ||||
| Seed | Dec 20, 2017 |
Key People
Founding team and executive leadership
Amphista Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| BioMotiv | Series B, Series A |
| Forbion | Series B |
| Advent Life Sciences | Series B, Seed, Series B Extension, Series A |
| European Investment Fund | Seed, Series A |
| Gilde Healthcare | Series B |
| Scottish Investment Bank (Scottish Enterprise) | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 51% MoM.
- Apr 17, 2026
Three presentations scheduled at the AACR 2026 Annual meeting.
Amphista Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amphista Therapeutics's valuation, stock price, and market status.